Transcranial Electric Stimulation for Health & Longevity - Quick Reference Sheet

Transcranial Electric Stimulation for Health & Longevity

Created on 10/03/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Transcranial electric stimulation, a drug-free technique passing weak current through scalp electrodes, is studied for mood, memory and sleep. For low mood, evidence leans positive but mixed; a home headset is approved for depression. Pain, migraine, sleep and stroke-recovery signals rest on smaller or lower-certainty studies; results for healthy older adults are thin. Main risks: skin redness, rare burns and, when treating depression, an uncommon swing into overly elevated mood. (Full Review)

Protocol

Depression, home tDCS
2 mA for 30 minutes
Anode F3, cathode F4; 5 sessions weekly for 3 weeks, then 3 weekly for 7 weeks
Cognitive aging, tDCS plus training (PACt-MD)
2 mA for 30 minutes
Anode Fz, cathode Iz, before computer-based cognitive training; 5 days weekly for 8 weeks, then 5-day boosters every 6 months
Insomnia, high-frequency tACS
77.5 Hz at 15 mA for 40 minutes
Forehead and behind-the-ear (mastoid) electrodes, on 20 weekdays over 4 weeks
Time to effect
Depression
By week 4
Scores separated from sham by week 4 and widened by week 10
Insomnia
Within 4 weeks
Sleep quality improved with high-frequency tACS
Memory, tACS
Day 2–3
Memory gains appeared by day 2–3 of a 4-day course

Benefits

Contraindications
  • Epilepsy or any history of seizures (including withdrawal or provoked seizures)
  • Implants in the brain or skull, any active implanted medical device, ferromagnetic (magnetizable) metal in the head, or skull defects
  • Current mania or psychosis, or a history of either (including bipolar type 1 or 2 disorder)
  • Pregnancy or breastfeeding
  • Severe insomnia (under 4 hours of sleep nightly) or sleep apnea, when used for depression
  • Treatment-refractory depression (inadequate response to 2 or more adequate antidepressant trials), outside the approved home-device indication
  • Broken, inflamed or diseased skin at the electrode sites (e.g., active scalp eczema)
Key Interactions
  • Sodium-channel-blocking anticonvulsants (carbamazepine; theoretical: oxcarbazepine, lamotrigine, phenytoin): monitor, reduced effect
  • NMDA antagonists (dextromethorphan; theoretical: memantine, ketamine): caution, loss of effect
  • Calcium-channel blockers (flunarizine; theoretical: verapamil): monitor, reduced effect
  • SSRIs (citalopram, escitalopram, sertraline): caution, possible mania
  • Benzodiazepines (lorazepam, clonazepam, alprazolam): caution, altered effect
  • Dopaminergic drugs (levodopa, ropinirole): monitor, unpredictable effect
  • Cholinesterase inhibitors (rivastigmine; theoretical: donepezil, galantamine): monitor, reduced effect
  • Beta-blockers (propranolol; theoretical: metoprolol): monitor, shorter effect
  • Stimulants (amphetamine; theoretical: methylphenidate): monitor, prolonged effect
  • Nicotine (patches, gum, tobacco): caution, reduced effect
  • Serotonergic or mood-elevating supplements (St John's wort, SAMe, 5-HTP): caution, possible mania (theoretical)
  • Other brain stimulation (magnetic stimulation, electroconvulsive therapy): avoid same-period combination (theoretical)
  • Cognitive training: monitor, no proven added effect

Risk & Side Effects

  • High: Skin redness and irritation under the electrodes
  • Medium: Treatment-emergent mania or hypomania; cognitive trade-offs; skin burns
  • Low: Seizure provocation
  • Speculative: Reversed effects with non-standard dosing; unknown effects of years-long use

Monitoring

Marker Target Why
PHQ-9 depression score No established target; track change from own baseline Tracks mood benefit
Mania screen (YMRS or a self-rated equivalent) No established target; track any rise from own baseline Safety check: elevated mood stops use
MoCA cognitive score No established target; track change from own baseline Tracks cognitive goals
Sleep score (PSQI or ISI) No established target; track change from own baseline Tracks sleep goals
Pain intensity (0–10 rating) No established target; track change from own baseline Tracks pain goals
Electrode-site skin inspection No established target; track redness against pre-session skin Safety check: blister or broken skin pauses use

Cadence: Skin check at every session; mood and mania screens weekly for the first 4 weeks, then every 4 weeks during the course; goal-specific questionnaires at weeks 4 and 10; repeat cognitive testing at the end of the course and 3–6 months later

Qualitative Assessment

  • Mood stability, motivation and enjoyment of daily activities
  • Unusually elevated mood, racing thoughts or reduced need for sleep (warning signs)
  • Mental clarity, word-finding and everyday memory, such as names and appointments
  • Sleep onset, night waking and morning restedness
  • Steadiness when walking while talking or carrying objects
  • Scalp comfort, headaches or lingering skin redness after sessions